Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

788
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
788
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Drug Regulation01:25

Drug Regulation

1.9K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The endoplasmic reticulum is a target organelle for trivalent dimethylarsinic acid (DMAIII)-induced cytotoxicity.

Toxicology and applied pharmacology·2012
Same author

(E)-1-{4-[Bis(4-bromo-phen-yl)meth-yl]piperazin-1-yl}-3-(4-eth-oxy-phen-yl)prop-2-en-1-one.

Acta crystallographica. Section E, Structure reports online·2012
Same author

(E)-1-{4-[Bis(4-bromo-phen-yl)meth-yl]piperazin-1-yl}-3-(4-methyl-phen-yl)prop-2-en-1-one.

Acta crystallographica. Section E, Structure reports online·2012
Same author

(E)-3-(1,3-Benzodioxol-5-yl)-1-{4-[bis-(4-meth-oxy-phen-yl)meth-yl]piperazin-1-yl}prop-2-en-1-one.

Acta crystallographica. Section E, Structure reports online·2012
Same author

Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.

PloS one·2012
Same author

Metabolism studies of casticin in rats using HPLC-ESI-MS(n).

Biomedical chromatography : BMC·2012

Related Experiment Video

Updated: Sep 20, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

Framework Development for Clinical Comprehensive Evaluation of Drugs-a Study Protocol Using the Delphi Method and

Chi Zhang1,2,3, Er-Li Ma4, Bing-Long Liu4

  • 1School of Medicine, Tongji University, Shanghai, China.

Frontiers in Pharmacology
|June 6, 2022
PubMed
Summary

This study introduces a novel two-level framework for evaluating drug value in healthcare decisions. It uses the Delphi method and Analytic Hierarchy Process (AHP) to assess drug safety, efficacy, cost, and other factors for better evidence-based decision-making.

Keywords:
analytic hierarchy processclinical comprehensive evaluation of drugsdelphi methodframeworkprotocol

More Related Videos

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

12.8K
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.3K

Related Experiment Videos

Last Updated: Sep 20, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

12.8K
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC

Published on: May 10, 2016

12.3K

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Clinical Decision Science

Background:

  • Evaluating drug value for healthcare decisions is complex, requiring trade-offs among multiple objectives.
  • Existing guidelines for drug evaluation need refinement for specific diseases and drugs.
  • A systematic approach is needed to integrate diverse factors into a comprehensive drug assessment.

Purpose of the Study:

  • To develop a two-level framework for the clinical comprehensive evaluation of drugs.
  • To establish a robust methodology for weighting and scoring drug evaluation components.
  • To provide a tool for evidence-based decision-making in healthcare regarding drug adoption and use.

Main Methods:

  • Development of a two-level evaluation framework based on the Chinese Guideline for Clinical Comprehensive Evaluation of Drugs.
  • Validation of second-level components using the Delphi method.
  • Determination of index weights and scoring criteria via the Analytic Hierarchy Process (AHP).
  • Integration of therapeutic effects and evidence quality into scoring criteria.

Main Results:

  • A validated two-level framework with defined indicators (safety, efficacy, cost-effectiveness, novelty, suitability, accessibility).
  • Established index weights and scoring criteria through Delphi and AHP.
  • A method for calculating a comprehensive drug score based on evaluated evidence.

Conclusions:

  • The developed framework offers a structured approach to drug value assessment.
  • The methodology ensures objective evaluation by incorporating expert consensus and hierarchical analysis.
  • The comprehensive drug score facilitates informed, evidence-based healthcare decisions.